AstraZeneca PLCAZN:LSE

4,175.5
15.00 / 0.36%
2.12m
4.25 %
0.5418
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 28 2015 16:07 BST.

Consensus recommendation

As of Jul 24, 2015, the consensus forecast amongst 36 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy6
Outperform8
Hold16
Underperform3
Sell2
No opinion0

Research Reports

MarketLine (a Datamonitor Company)
Charles Stanley Securities

Share price forecast

Share price forecast information is not available for AstraZeneca PLC. View Full Financials

Dividends

In 2014, AstraZeneca PLC reported a dividend of 2.77 USD, which represents a 208.17% increase over last year. The 31 analysts covering the company expect dividends of 2.81 USD for the upcoming fiscal year, an increase of 1.17%. View Full Financials

Div growth (TTM)+208.17 %
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Apr 24, 2015, AstraZeneca plc reported 1st quarter 2015 earnings of 1.08 per share. This result was in line with the consensus of the 10 analysts following the company and under-performed last year's 1st quarter results by 7.69 %.
The next earnings announcement is expected on Jul 30, 2015. View Full Interim Financials

Average growth rate+1.59 %

AstraZeneca plc reported annual 2014 earnings of 4.28 per share on Feb 05, 2015. View Full Annual Financials

Average growth rate-9.98 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

AstraZeneca PLC had 1st quarter 2015 revenues of 6.06bn. This bettered the 5.98bn consensus of the 12 analysts covering the company. This was 5.60 % below the prior year's 1st quarter results. View Full Interim Financials

Average growth rate-1.31 %

AstraZeneca PLC had revenues for the full year 2014 of 26.10bn. This was 1.49% above the prior year's results. View Full Annual Financials

Average growth rate-5.59 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.